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Abstract  
Fabry disease represents an X-linked systemic lysosomal storage disorder due to mutations in 
the GLA gene encoding alfa galactosidase and was originally described in 1898. Nowadays, 
the detection of an increasing number of genetic variants and mutations requires individual 
assessment. Recent newborn screening studies detect a prevalence of 1:1250 regarding GLA 
mutations. Specific enzyme replacement therapy consisting of agalsidase alfa or agalsidase 
beta has been available since 2001. Still many patients are diagnosed only late in their disease 
course. This diagnostic delay reflects that non-classical phenotypes are more common than 
previously thought. Plasma lyso-GL3 levels have emerged as the most accepted diagnostic 
biomarker in routine clinical use, complementing enzyme activity measurements and genetic 
analysis. Lysosomal deposits of glycosphingolipids (mostly GL3) in kidney tissue, are 
characteristic for Fabry disease. Kidney biopsies are important in clinical practice and have a 
key role in diagnosis, research and understanding of the pathogenesis of Fabry disease. 
Enzyme replacement therapy, especially given early, can slow down the progression of Fabry 
disease, such as nephropathy and cardiomyopathy. This is evident despite the lack of a 
sufficient number of randomized placebo-controlled trials (RCT). In addition, recent studies 
point towards a dose-effect of enzyme replacement. Major causes for treatment failures are 
therapy initiation at a too advanced disease state and the formation of neutralizing antidrug 
antibodies. Recent advances in therapy are represented by migalastat, an oral pharmacological 
chaperone, already in routine clinical use, and clinical studies to introduce new therapies. 
 
The changing landscape of Fabry disease  
Fabry disease is a rare X-linked lysosomal storage disorder due to mutations in the GLA gene 
causing complete or partial deficiency of the enzyme alfa galactosidase A ( -Gal A) and 
subsequent slow accumulation of mainly globotriaocylceramide (Gb3 or GL3) and its 
deacylated derivative globotriaosylsphingosine (lyso-GL3, also called Lyso-Gb3) in several 
cell types and body fluids. Early and often asymptomatic cellular damage typically precedes 
various degrees of organ affection and late organ failure. Clinical symptoms  are highly 
variable and mostly nonspecific1. Kidney cells, cardiomyocytes and vascular endothelium are 
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target cells of particular interest in a usually slowly progressive disease. Major complications 
are secondary to renal, cardiac and/or central nervous system affection, usually from the 
fourth decade onward 2. The disease has had a long journey from the original description of 
cutaneous angiokeratoma in 1898 3 to the current recognition of a treatable highly complex 
and heterogenous multisystem disease carrying a high rate of morbidity and mortality 4. The 
grim natural disease course in the era before enzyme replacement therapy should not be 
forgotten and was described in 2002 by Branton et al. 5 in 105 hemizygous classical male 
patients, only 25 of 105 patients survived until the age of 50 and no patients survived past age 
60 years. Before the advent of dialysis and kidney transplantation, the most common cause of 
death was uremia, at a mean age of 41 years 6. Overall, before enzyme replacement was 
available a reduced life span of about 25 years in males and 10 years in females was expected 
compared to the general population 7. Although the pathophysiology still is only partly 
understood (Figure 1) the increasing knowledge of the complexity of mutations and disease 
manifestations has been fueled by a surge of clinical research and numerous publications 
following the introduction of enzyme replacement therapy nearly 20 years ago. Agalsidase 
alfa and agalsidase beta was approved in Europe and US (agalsidase beta only) in 2001, 
licensed doses are 0.2 mg/kg/every other week and 1.0 mg/kg/every other week respectively 8, 
9. Ten years follow-up registry data clearly demonstrate a modifying effect of ERT on serious 
organ complications and mortality10, 11, and there has been a change allover in mortality from 
predominantly kidney to cardiac deaths 12, 13. 
Historically, the disease has been hampered by diagnostic delay and subsequent delays of 
therapeutic intervention until irreversible organ damage prevails. Hence, the median age at 
diagnosis was 24 years in males and 31 years in females in a survey of more than 2200 
patients, the median time between onset of symptoms (usually neurological pain and 
gastrointestinal dysfunction) and diagnosis was about 11 years in both sexes 14. The rationale 
for the increasing focus on early therapy has been clearly demonstrated by several reports 
highlighting the serious prognostic impact of diagnostic and therapeutic delays15, 16.  
 
Epidemiology, genetics and characterization of phenotypes 
Over the last two decades general knowledge of Fabry disease and therapeutic challenges 
have changed dramatically and prognosis has improved for several reasons. Enormous 
progress in genetic sequencing technology has led to a paradigm change in the understanding 
of the complexity of genotype – phenotype interactions. Recently, a general description of 
clinically relevant categories of variants in Mendelian disorders using the terminology 
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“pathogenic”, “likely pathogenic”, “uncertain significance”, “likely benign” or “benign” has 
been suggested 17, 18. This is especially relevant for the classification of clinical phenotypes 
harboring GLA missense mutations accounting for about 60 % of more than 900 known 
mutations (Human Gene Mutation Database, www.hgmd.org). Importantly,  the increasing 
incidence and prevalence of late-onset non-classical mutations and genetic variants of unclear 
significance with milder disease phenotypes have been acknowledged 17, 19 with symptoms 
often confined to a single organ (especially cardiac), and some of these presumably have no 
clinical disease at all 17, 20. The wide phenotypic spectrum of disease severity, even within the 
same family, and the fact that not all mutations are disease causing (e.g. polymorphisms) 
highlight the necessity of careful individual diagnostic and prognostic assessment to allow 
correct and timely intervention as well as avoidance or postponement of unnecessary high-
cost treatment in patients with non-disease causing mutations or very mild disease 19-22. The 
increasing birth prevalence of GLA mutations from previous estimates of 1:40.000 – 170.000 
23 up to 1:1250 in newborn screening studies 19, 24, 25 reflects the existence of a majority of 
non-classical mutations and variants of unknown significance where natural history and 
effectiveness of enzyme replacement are unknown 19. Currently, research on clinically 
relevant genotype-phenotype relationships are increasingly prioritized. Clear criteria exist for 
diagnosis of classical early onset Fabry disease (also called Type 1) with absent or low levels 
of enzyme activity and typical symptoms 4. However, a precise diagnosis may be difficult in 
late-onset, non-classical (also called Type 2) male and female patients harboring any variant 
in the GLA gene with residual enzyme activity and variable X chromosome inactivation 
patterns (females), often presenting with cardiac, minimal or unclear symptoms26, 27  in early 
or late adulthood 17, 28, 29. A widely used algorithm for diagnosing Fabry disease in these latter 
categories has been published by van der Tol et al. 19, 30, 31.  
 
 
New insight in effectiveness of enzyme replacement therapy 
The introduction of intravenous enzyme replacement has fueled a tremendous amount of 
research opening many new avenues for collaborative work involving experts from key 
medical specialties. The way forward has served as a model for learning and organizing of 
clinical research, defining challenges and caveats in the field of metabolic rare diseases 15, 32. 
Although enzyme replacement therapy undoubtedly has turned Fabry disease into a treatable 
disease, it has become obvious that intervention should be regarded as a disease modifier 
rather than a cure, and persistent risk of serious complications and increased mortality raises 
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major concern over current therapeutic strategies 32, 33. Furthermore, numerous observational 
studies and case series published the latter decade have disclosed a conundrum of Fabry 
disease heterogeneity highlighting the necessity of individual assessment and targeting of 
therapy, even in patients within the same family  15, 34, 35. Given a slowly progressive 
heterogenous disease, new light has been shed on the validity of biases and limitations of few 
small RCT`s of short duration in comparison with numerous long-term follow-up studies with 
a high number of patients36-38. The value of analysis of unpooled data from systematic 
comprehensive literature searches of observational studies and case series/reports through 
January 2017 has recently been reported 38. These much larger patient cohorts and attempts to 
separate data among relevant clinical phenotypes (children, females, males, classical and non-
classical), some of them treated for more than 15 years, have provided new insight which 
helps the treating physician better define individual patient risk and adequate therapeutic 
goals. Importantly, this knowledge has strengthened the need for an individual comprehensive 
multidisciplinary approach, carefully addressing genotype, phenotype, family history and 
biomarkers including kidney histology when possible 34, 35, 39, 40.  
 
Individual therapeutic goals and risk profiles 
Organ specific therapeutic goal recommendations, covering altogether 249 publications (67 % 
male patients including 36 clinical trials), suggest a significant slowing of decline of eGFR 
and reduction/stabilization of cardiac mass (adult males). The kidney and cardiac therapeutic 
benefits provide new information expanding the knowledge reported in a previous meta-
analysis 33. Although a cardiac benefit was suggested in both sexes, recent data generally were 
less robust in females, likely because of a wider disease spectrum ranging from asymptomatic 
to severely (rare) affected individuals 40. Interestingly, quality of life outcomes was improved 
in both sexes 34, 40. The prognostic importance of younger age and absence of organ damage 
when enzyme replacement therapy is initiated have been shown in several studies 10, 41. 
Germain et al. 10 defined “low renal involvement” (LRI) as UPCR < 0.5 g/g and less than 50 
% sclerotic glomeruli in a well-defined observational 10 year follow-up study of 52 classical 
patients (2 females), mean age 30 years and normal eGFR at start of agalsidase beta 1.0 
mg/kg/every other week. The LRI group (n=32) was younger (mean 25 years at treatment 
initiation) than the “high renal involvement” group and showed less deterioration of eGFR 
(mean slope -1.89 versus -6.82 ml/min/1.73 m2/year). Of note, 94 % of the patients were alive 
at the end of the study, and 81 % did not experience any events. In patients on enzyme 
replacement therapy lower eGFR and higher levels of proteinuria strongly predict faster 
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disease progression 16. Supplemental therapy with RAAS-inhibition to lower proteinuria to ≤ 
0.5 g/day and potentially stabilize GFR should be considered in classical patients with 
reduced GFR and severe proteinuria 15, 42. The effects of enzyme replacement therapy on 
cerebrovascular events remains unknown, although a recent meta-analysis suggest a potential 
benefit on stroke prevention43. Though no clear consensus exists, recommendations for 
considering withdrawal of enzyme replacement in patients with advanced disease have also 
been published 44.  
 
Is higher agalsidase dose beneficial?  
Although in vitro mg per mg equipotency of agasidase alfa and beta has been demonstrated 45 
the discussion about clinical equipotency of licensed drug regimens remains unsettled. The 
beneficial effect of higher cumulative agalsidase dose on kidney histology has been reported 
by Skrunes et al. 41 in serial kidney biopsies in 20 classical patients (median age 21 years, 12 
males) with stable microalbuminuria and normal measured GFR followed for ten years. A 
clear dose-dependent effect on clearance of podocyte GL3 deposits was found in this cohort, 
and residual lyso-GL3 correlated with the cumulative enzyme dosage in male patients. The 
clinical benefits of higher enzyme doses have been corroborated and likely underscored in a 
larger observational multicenter study with systematic follow-up of a high number of patients 
of both sexes from three European Fabry centers. The compulsory switch from agalsidase 
beta 1.0 mg/kg/every other week to agalsidase alfa 0.2 mg/kg every other week in many 
patients (due to the worldwide shortage of agalsidase beta supply from June 2009 to January 
2012) and subsequent re-switch to agalsidase beta 1.0 mg/kg every other week in a number of 
patients showed conspicuous dose-dependent benefits regarding GFR-slopes, lyso-GL3 levels 
and gastrointestinal symptoms 46. Moreover, an overview of available evidence indicates that 
higher doses of agalidase are beneficial given an optimal timing of therapy and selection of 
patients with classical phenotypes 47, 48. Importantly, the majority of literature-based 
observations of dose-dependent clinical effects so far are confined to classical male patients, 
and further long-term studies in expanded cohorts of high-risk patients are warranted. Long-
term data on therapy outcome in general are insufficient in female patients and sex mixed 
study populations, likely because of variations in X-chromosome inactivation which are 
usually not reported in clinical studies 34, 40. This may also in part be the reason why no 
differences were found in clinical events in a recent European multicenter study including a 
mixture of classical and non-classical patients (n=387 (192 females), mean age 46 ±15 years 
at therapy initiation) comparing licensed doses of agalsidase alfa and beta 49. However, a 
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more robust decrease of lyso-GL3 and better reduction in left ventricular mass were reported 
in patients receiving a higher enzyme dose 49. There is one study reporting kidney benefit of 
increasing the dose of agalsidase alfa to 0.2 mg/kg every week in a limited number of patients 
50, but no such evidence is reported for agalsidase beta. Although current enzyme substitution 
regimens fail to normalize elevated lyso-GL3, a clear dose- and age-dependent decrease of 
lyso-GL3 has been observed after therapy 41, 49, 51, and the recent therapeutic goal initiative 
recommends to strive at the lowest possible level of lyso-GL3 35. More importantly, enzyme 
replacement therapy has limited effect when started late in the course 15, 49, 52, 49 . 
   
Neutralizing anti-agalsidase antibodies 
A major reason for treatment failure is formation of neutralizing antidrug antibodies (ADAs) 
which is reported to affect 40 % of male patients treated with agalsidase beta or alfa and leads 
to subsequent decline of GFR and increase in lyso-GL3 56. Lenders et al. elegantly 
demonstrated that agalsidase dose escalation may overcome the detrimental inhibitory effects 
of these antibodies 56. A potential therapeutic approach has recently been published, 
highlighting the need of standardizing assays and methods for individual dose escalations to 
obtain a saturated ADA status 57. Furthermore, future prospective studies are warranted to 
elucidate the clinical impact of ADAs 57. The role of immunosuppressive therapy is unknown. 
 
Initiation of pharmacologic therapy: How early is early enough? 
The strategy of “early treatment” of Fabry disease has been a major focus and is based on the 
experience in classical patients that progressive disease is more frequent when therapy is 
delayed until irreversible organ damage is manifest 16, 17, 52. Our experience in a youngish 
classical symptomatic patient cohort with normal heart and normal measured GFR and 
normo/microalbuminuria suggests that enzyme replacement should be initiated within the 
teens (before the age of 18 years) 41, 51, 58 with the goal to prevent or delay the progression to 
irreversible kidney and heart damage. This “window of opportunity” approach is supported by 
several authors 15, 39, 44. Earlier start of therapy in childhood has to be decided on individual 
basis in cases with severe symptoms and signs. A systematic follow-up to define the 
individual appropriate window for “early therapy”, often at higher age, is mandatory 
especially in slowly progressive non-classical late onset cases (usually females) 34, 35, 40.  
 
New therapies 
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The need for more effective therapy of Fabry disease has stimulated research addressing 
alternative mechanisms to enhance efficacy of endogenous or infused enzyme. Substrate 
reduction therapy 59 and gene therapy trials as listed by ClinicalTrials.gov 60 are currently 
recruiting patients for phase I-III studies.  
Migalastat, a small-molecule pharmacological chaperone first approved in Europe 2016 and 
US in 2018, was developed as a stabilizer of specific mutant (amenable) forms of α-Gal to 
facilitate its normal lysosomal trafficking 61, 62. In an 18-month phase III trial in 
predominantly female patients, this agent was well tolerated and was associated with a 
decrease in left ventricular mass index. Migalastat and enzyme replacement therapy had 
similar effects on kidney function 62. Another phase III study showed modest reduction of GL 
3 in interstitial capillaries and glomerular cells after six and 12 months of therapy 61, 63. Thus, 
Migalastat could represent an oral monotherapy alternative therapy to enzyme replacement in 
respective patients 62. Notably, the concept of in vitro and in vivo amenability is under 
scrutiny, especially in patients with lower range (< 10 %) enzymatic activity 64. 
Pegunigalsidase alfa, a novel PEGylated enzyme replacement agent, has prolonged halflife 
and potential benefits regarding immunogeneicity compared to agalsidase. Phase I/II-studies, 
as well as switch (from agalsidase alfa) and comparative (agalsidase beta) studies have 
recently been launched 65. 
 
Plasma and tissue specific markers 
There is no single ideal biomarker in Fabry disease. Elevated plasma lyso-GL3 has been 
designated a hallmark of Fabry disease 66. Currently, measurement of plasma lyso-GL3 has 
increasingly replaced plasma and urine GL3 as the most significant and technically more 
easily measured non-invasive diagnostic biomarker 67, supplementing standard measurements 
of leukocyte GLA enzyme activity and genetic analysis. Lyso-GL3 allows a better 
discrimination between patients with classical and non-classical disease and subjects without 
Fabry disease. Furthermore, elevated lyso-GL3 has been linked to clinical events and a higher 
disease burden 21, 29, 68. Since skewed X-chromosome inactivation may differ between cells 
and organs in females, a normal plasma lyso-GL3 value does not rule out the existence of 
Fabry disease 29, 67, 68. After initiation of enzyme replacement therapy, a rapid reduction in 
lyso-GL3 levels is seen in classical males, while a slower decline or stabilization typically 
follows in most of non-classical patients and females 49, 69. Beyond being a marker of disease 
lyso-GL3 is likely also directly involved in the disease pathogenesis via stimulation of 
inflammatory and fibrotic mechanisms which are upregulated in Fabry disease 53, 54. A novel 
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experimental finding suggesting persistent dysregulated inflammatory signaling in spite of 
agalsidase-induced podocyte GL3 elimination was recently published 55, shedding new light 
on potential contributions of glycolipid stimulated inflammatory markers to vascular 
remodeling and progressive vasculopathy. Laboratory assay and limited availability of a 
laboratory assay for lyso-GL3 are still a challenge in many centers. Further elucidation of the 
specificity of urinary lyso-GL3 analogues is a matter of ongoing research, especially in late-
onset variants with cardiac disease 70. Markers of chronic inflammation in Fabry disease are 
not yet implemented in clinical practice 53. 
In tissue biopsies abundant lysosomal deposits of glycosphingolipids, mainly GL3, are 
hallmarks of Fabry disease, these are especially conspicuous in podocytes 71, 72 and can easily 
be diagnosed by bedside stereomicroscopy immediately after a kidney biopsy 73.  Recently, 
measurement of abnormal podocyturia has been tested as a potential early diagnostic and 
prognostic non-invasive tool in ascertainment of progressive disease and disease burden in 
patients with classical disease 74. Increased podocyturia has even been reported in very young 
classically affected children 75. Larger scale validation of the future role of this parameter are 
needed. General cardiac biomarkers may also be useful in establishing a full assessment and 
risk profile for the patient 76.  
 
Kidney biopsies 
Routine clinical laboratory tests (eGFR and albuminuria) are insensitive markers of early 
progressive Fabry nephropathy. On the other hand, the assessment of specific and non-
specific reversible or irreversible histologic changes provides early information on kidney 
damage even in patients with normal GFR and normoalbuminuria. These are crucial 
diagnostic findings for choosing optimal therapeutic strategies and follow-up of high-risk 
patients 41, 58, 77-80. In general, a kidney biopsy has been recommended in Fabry patients with 
atypical symptoms and unclear diagnosis, often with normal kidney function, as well as in 
cases with unexpected disease course and suspected concomitant diseases 15, 30, 31. A 
conspicuous finding in recent case series is the discrepant beneficial effect of enzyme 
replacement therapy on removal of GL-3 inclusion from podocytes, glomerular capillary 
endothelial and mesangial cells contrasting with a worrisome lack of vascular protection. In 
the study of Tøndel et al. 51 in 12 young classical patients (median age 16.5 (range 7-33) years 
at treatment initiation, one female) treated for five years, total clearance of podocyte GL-3 
was obtained in the youngest patient and microalbuminuria normalized in nearly half of the 
patients. These findings were further expanded by Skrunes et al. 41 reporting paired serial 
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kidney biopsies after 10 years treatment in an expanded cohort (20 classical patients, 12 
males, median age 21 (range 7-61) years) confirming a dose-dependent effect on elimination 
of podocyte GL3 deposits (Figure 2) contrasting with a persistent failure to protect smooth 
muscle cells in media layers of kidney arterioles/arteries 41. This finding suggests that current 
therapy is insufficient to prevent long-term vascular complications. The underscoring of 
serious vasculopathy even in young patients was further highlighted by the randomized 
multicenter study of 31 classical pediatric males with minimal disease symptoms and normal 
measured GFR (median age 12 (range 5-18) years) receiving enzyme replacement for 5 years 
comparing two treatment regimens (0.5 mg/kg 2-weekly (n=16) or 1.0 mg/kg 4-weekly 
(n=15) 80. Six patients (mean baseline age 15.5 (range 14-17) years) had repeated paired 
kidney biopsies, arteriopathy (replacement of arterial/arteriolar muscle cells with hyaline-like 
material) was evident in all baseline biopsies and surprisingly showed progression in all but 
one patient despite a mean reduction of lyso-GL3 of 71 %.  
Systematic kidney biopsies are underused in Fabry disease and further prospective studies are 
warranted to help clarify disease mechanisms and potential correlation with clinical 
phenotypes. Histologic examinations may allow early differentiation between patients with 
“high”, “low” or “no risk” of progressive tissue damage, and sometimes unnecessary 
treatment can be avoided when normal or only minimally affected tissue or superimposed 
disease is identified20, 30, 73. Kidney biopsies provide the earliest and most sensitive insight 
into important cellular and vascular involvement, which are surrogate markers of disease 
activity. New unbiased stereological histologic methods 79 have shown capacity for 
assessment of therapeutic response after one year`s therapy 61, 79. To detect and expand 
potentially relevant pathophysiological mechanisms, kidney biopsies can be used beyond 
routine diagnostics by the application of omics-related technologies. A preliminary study 
from our institution exploited next generation mRNA sequencing of mRNA from micro-
dissected nephron compartments of serial long-term kidney biopsies with Fabry nephropathy. 
First analyses pointed towards increased expression of genes e.g. related to extracellular 
matrix, immune response and inflammation compared to baseline tissues 81. Thus, RNA 
sequencing is feasible in archival Fabry disease kidney biopsies and may help to delineate 









Fig. 2. Histology of Fabry Nephropathy. Dose-dependent clearance of podocyte GL3 (red 
arrows) in two brothers with classical Fabry disease, aged 13 years and 15 years at initiation 
of enzyme replacement therapy. Biopsies are baseline (upper and lower left column, 
respectively), and after 3, 7 and 13 years agalsidase therapy. After 6 years of enzyme 
replacement therapy the younger brother (upper row) was switched to agalsidase-beta 1.0 
mg/kg every other week. After the switch, the podocytes were virtually completely cleared of 
GL3, whereas his older brother (lower row), who received a lower cumulative agalsidase 
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